Showing 4331-4340 of 5957 results for "".
- Study: Early Anti-VEGF Treatment of Diabetic Retinopathy Slows Progression but Yields No Benefit to Visual Acuityhttps://modernod.com/news/study-early-anti-vegf-treatment-of-diabetic-retinopathy-slows-progression-but-yields-no-benefit-to-visual-acuity/2481399/While early treatment of diabetes-related eye disease slowed progression to severe disease, it did not improve visual acuity compared with treating more severe disease once it developed, according to a clinical study from the DRCR Retina Network. The study was funded by the National Eye Institute
- Novaliq Plans to File a Marketing Authorization Application for CyclASol in the EU for Dry Eye Diseasehttps://modernod.com/news/novaliq-plans-to-file-a-markting-authorization-application-for-cyclasol-in-the-eu-for-the-treatment-of-dry-eye-disease-in-july-2023/2481396/Novaliq announced its plans for filing a marketing authorization application (MAA) CyclASol (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED), in the European Union. The Committee for Medicinal Products for H
- RxSight Announces Pricing of Public Offering of Common Stockhttps://modernod.com/news/rxsight-announces-pricing-of-public-offering-of-common-stock/2481395/RxSight, maker of the RxSight Light Adjustable Lens system, announced it has priced its underwritten public offering. RxSight expects to sell 4 million shares of its common stock at a price to the public of $12.50 per share. RxSight has granted the underwriter a 30-day op
- Omeros Receives $200 Million Milestone Payment from Raynerhttps://modernod.com/news/omeros-receives-200-million-milestone-payment-from-rayner/2481391/Omeros announced that Rayner has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021, pursuant to which Omeros sold its ophthalmology product Omidria to Rayner in December of 2021. Omeros received
- Nidek Launches Cube Alpha Ophthalmic Surgical Systemhttps://modernod.com/news/nidek-launches-cube-a-ophthalmic-surgical-system/2481390/Nidek has announced the launch of the Cube α ophthalmic surgical system, which is designed to incorporate new ultrasound technology to deliver more powerful and effective phacoemulsification. According to Nidek, the Cube α incorporates Gyro torsional technolog
- Viridian Appoints Scott Myers as President and Chief Executive Officerhttps://modernod.com/news/viridian-appoints-scott-myers-as-president-and-chief-executive-officer/2481388/Viridian Therapeutics has appointed Scott Myers as President and Chief Executive Officer, as well as a member of the Board of Directors, effective February 6, 2023. He succeeds Jonathan Violin, PhD, who has led Viridian since its inception in 2020. “Our progres
- Tracey Technologies Launches iTrace Prime Upgraded Software for iTrace Aberrometerhttps://modernod.com/news/tracey-technologies-launches-itrace-prime-upgraded-software-for-itrace-aberrometer/2481384/Tracey Technologies announced the release of iTrace Prime, an upgraded software for the iTrace Ray Tracing aberrometer and corneal topographer. This new software version (7.0) adds new features that improve the range of information able to be gathered from a single device, accordi
- Nidek and Hoya Vision Care Enter Global Partnershiphttps://modernod.com/news/nidek-and-hoya-vision-care-enter-global-partnership/2481381/Nidek has announced a partnership with Hoya Vision Care that would allow Hoya's customers access to Nidek's optical products, services and instruments through both local distributors. Financial terms of the deal were not disclosed. The aim of the partnership
- Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-6-month-results-from-oasis-extension-study-with-suprachoroidal-cls-ax-in-wet-amd/2481380/Clearside Biomedical announced positive results from the extension study of its OASIS phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in wet age-related macular degeneration (AMD) parti
- Nidek Launches the AL-Scan M Optical Biometerhttps://modernod.com/news/nidek-launches-the-al-scan-m-optical-biometer/2481376/Nidek has announced the launch of the AL-Scan M Optical Biometer and the MV-1 Myopia Viewer software. The AL-Scan M incorporates 3D auto tracking and auto shot functions, designed for easy operation and quick measurement similar to an auto refractometer. Nidek says the features&nbs